The August 20, 2018, article by Li et al entitled “Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial” (J Clin Oncol 36:2532-2537, 2018) was published with errors in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Baselga’s COIs were given as:

Jose Baselga

Leadership: Infinity Pharmaceuticals, Varian Medical Systems, Bristol-Myers Squibb

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Varian Medical Systems, Bristol-Myers Squibb, Tango Therapeutics, Foghorn Therapeutics

Consulting or Advisory Role: GRAIL, Eli Lilly, Novartis, Genentech, Janssen

They should have read as:

José Baselga

Leadership: Infinity Pharmaceuticals, Varian Medical Systems, Bristol-Myers Squibb, **GRAIL**

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Varian Medical Systems, Bristol-Myers Squibb, Tango Therapeutics, Foghorn Therapeutics, **Aura Bio-medical, Apogen, Northern Biologics**

Honoraria: PMV pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Northern Biologics

Consulting or Advisory Role: Eli Lilly, Novartis

Research Funding: Roche/Genentech

Patents, Royalties, Other Intellectual Property: Combination Therapy using PDK1 and PI3K inhibitors. Pending. MSK owned, listed as investigator. Jul 16 Use of phosphoinositide 3- kinase inhibitors for treatment of vascular malformations. Licensed. MSK owned, listed as investigator. Inhibition of KMT2D for the treatment of breast cancer. Pending. MSK owned, listed as investigator.

Travel, Accommodations, Expenses: Roche/Genentech, Daiichi, Bristol-Myers Squibb.

This has been corrected as of January 11, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02207>

The November 1, 2018, article by Cruz et al entitled “Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy” (J Clin Oncol 36:3134-3143, 2018) was published with errors in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Baselga’s COIs were given as:

José Baselga

Leadership: Varian Medical Systems, Bristol-Myers Squibb, Foghorn Therapeutics

Stock or Other Ownership: PMV Pharmaceuticals, GRAIL, Tango Therapeutics, Northern Biologics.

They should have read as:

José Baselga

Leadership: Varian Medical Systems, Bristol-Myers Squibb, **GRAIL, Infinity Pharmaceuticals**

Stock or Other Ownership: PMV Pharmaceuticals, GRAIL, Tango Therapeutics, Northern Biologics, **Juno Therapeutics, Infinity**

Pharmaceuticals, Varian Medical Systems, Foghorn, Aura Bio-medical, Apogen, Bristol-Myers Squibb

Honoraria: PMV pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Northern Biologics

Consulting or Advisory Role: Eli Lilly, Novartis

Research Funding: Roche

Patents, Royalties, Other Intellectual Property: Combination Therapy using PDK1 and PI3K inhibitors. Pending. MSK owned, listed as investigator. Use of phosphoinositide 3- kinase inhibitors for treatment of vascular malformations. Licensed. MSK owned, listed as investigator. May 16. Inhibition of KMT2D for the treatment of breast cancer. Pending. MSK owned, listed as investigator.

Travel, Accommodations, Expenses: Roche/Genentech, Daiichi, Bristol-Myers Squibb

This has been corrected as of January 11, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02205>